CHEST 2022 Guidelines: Perioperative Management of Antithrombotic Therapy
Dr. Chokri Ben Lamine, hematologist at King Faisal Specialist Hospital and Research Centre (KFSHRC), recently shared a post on X:
“Perioperative Management of Antithrombotic Therapy per CHEST 2022 Guidelines
1/ Key Color Code
Green: Continue
Orange: Individualize
Red: Stop
Always tailor by bleeding risk, CrCl, and surgery type!
2/ VKA (e.g. warfarin)
Continue until day -5 to -3
Restart PM of surgery day if no bleeding
Bridging? Only if high thrombotic risk
3/ DOACs (apixaban, edoxaban, rivaroxaban, dabigatran)
CrCl dependent!
Stop 2–3 days preop (longer if decreased CrCl or high bleeding)
Restart ~48–72h postop if low bleeding risk
4/ LMWH bridging
Don’t use for all patients!
Use if VKA held + high thrombotic risk
Last dose ≥24h preop
Resume Day 1–2 postop depending on bleeding
5/ Antiplatelets
•Aspirin: Y/N by bleeding risk and cardiac history
•Clopidogrel/Ticagrelor: Hold 5–7 days before
•Prasugrel: Hold at least 7 days preop
Restart Day 1–2 postop
6/ Fondaparinux:
Stop ~3 days preop
Restart Day 1–2 postop
7/ Key Reminders
Don’t restart anticoagulation until ≥24h post-op
High-risk surgery = longer hold
Multidisciplinary planning essential
Always consider CrCl + bleeding/thrombotic risk!
Source:
Douketis JD, et al. Chest. 2022;162(5):e207-e243.
© American College of Chest Physicians.
Credits: Dr. Hazzaa Alzahrani for sharing.”
Stay updated on the latest with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals